Company news: Teva, Everyday Health

Share this article:

Teva reported Thursday that sales for the quarter ended June 30 were $5 billion, 19% more than sales for the same period last year, which held at $4.2 billion. US sales climbed 28% to $2.5 billion, with generics contributing just over $1 billion in sales and branded drugs added $1.3 billion to the US quarterly sales tally. Generic sales slipped 12% in Europe, to $884 million, compared to almost $1 billion in sales for the same period the year before. Europe embraced branded drugs to a larger extent this quarter, with $402 million in sales, a 46% of increase of sales during the same period last year. President and CEO Jeremy Levin said in a statement that the company is on track to meet the year's financial goals. Credit Suisse analyst Michael Faerm said in a research note that the results missed consensus estimates for sales that but operating expenses were well below expectations.

Everyday Health reported that advertising and sponsorship from healthcare companies grew 35% when compared to the first six months of 2011. The privately held firm, whose media portfolio includes a mix of video, mobile and social touchpoints, said revenue from its top 20 advertisers grew 31% for the first half of 2012, compared to the same period in 2011. The previously text-centric health information firm has undergone rapid changes, including the December launch of a video channel on YouTube, last September's TV series debut and the August 2011 hiring of SVP/GM Paul Slavin. The company has 25 digital health and life properties in the US and is increasing is global reach -- it announced in July that it was breaking into the UK with its first site, WhattoExpect.co.uk, in November and plans to launch EverydayHealth.co.uk in 2013.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Illumina inks deal with J&J, AstraZeneca, Sanofi

The goal is to develop companion diagnostics to match patients with cancer treatments.

Abbott deal highlights inversion inaction

Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.

Allergan reported to seek out Salix deal

The Wall Street Journal says the deal would add "another layer of intrigue" to the Allergan-Valeant hostilities.